scholarly journals Development in PaCO2 over 12 months in patients with COPD with persistent hypercapnic respiratory failure treated with high-flow nasal cannula—post-hoc analysis from a randomised controlled trial

2020 ◽  
Vol 7 (1) ◽  
pp. e000712
Author(s):  
Line Hust Storgaard ◽  
Hans-Ulrich Hockey ◽  
Ulla Møller Weinreich
Keyword(s):  
Hospital Admissions ◽  
Blood Gases ◽  
High Flow ◽  
Nasal Cannula ◽  
Control Group ◽  
High Flow Nasal Cannula ◽  
Exacerbation Rate ◽  
Post Hoc Analysis ◽  
Post Hoc

IntroductionPersistent hypercapnic failure in chronic obstructive pulmonary disease (COPD) is associated with poor prognosis. Long-term home non-invasive ventilation is recommended for patients with PaCO2 >7.0 kPa. Domiciliary high-flow nasal cannula (HFNC) reduces PaCO2 in short-term studies. This post-hoc analysis examines the effect of HFNC on PaCO2 levels, exacerbations and admissions in patients with COPD with persistent hypercapnic and hypoxic failures.MethodsThe original trial included 74 long-term oxygen-treated patients (31 HFNC treated/43 controls) with persistent hypercapnic failure (PaCO2 >6 kPa) who completed the 12-month study period. Baseline data included age, sex, blood gases, exacerbations and hospital admissions in the previous year. Data on blood gases were also recorded at 6 and 12 months for all patients. In addition, acute changes in blood gases after 30 min of HFNC use at site visits were examined, as were exacerbations and hospital admissions during study.ResultsPatients were comparable at baseline. After 12 months there was a 1.3% decrease in PaCO2 in patients using HFNC and a 7% increase in controls before HFNC use on site (p=0.003). After 30 min of HFNC at visits PaCO2 changed significantly, with comparable reductions, at 0, 6 and 12 months, including for controls who tried HFNC at study end (p<0.001). The exacerbation rate increased, compared with 12 months prestudy, by 2.2/year for controls (p<0.001) and 0.15/year for HFNC-treated patients (p=0.661). Hospital admission rates increased in the control group,+0.3/year from prestudy (p=0.180), And decreased by 0.67/year (p=0.013)for HFNC-treated patients.ConclusionThis post-hoc analysis indicates that HFNC stabilises patients with COPD with persistent hypoxic and hypercapnic failures, in terms of PaCO2, exacerbations and number of hospitalisations, whereas those not receiving HFNC worsened. This suggests that HFNC is a possible treatment for patients with persistent hypercapnic COPD.

scholarly journals Title High Flow Nasal cannula oxygen therapy in a general pediatric (non-intensive care) setting

2019 ◽  
Author(s):  
Louise Kooiman ◽  
Roelien Reimink ◽  
Veerle Langenhorst ◽  
Paul Brand ◽  
Jolita Bekhof
Keyword(s):  
Intensive Care ◽  
Respiratory Failure ◽  
Treatment Failure ◽  
Hospital Admissions ◽  
Work Of Breathing ◽  
High Flow ◽  
Nasal Cannula ◽  
Early Warning Score ◽  
High Flow Nasal Cannula ◽  
Vital Functions

Abstract Background: High flow nasal cannula therapy (HFNC) is being used increasingly for oxygen delivery in children with impending respiratory failure, however solid evidence of its effectiveness is sparse. Moreover, data on safety regarding its use outside of the Pediatric Intensive Care Unit (PICU), with flowrates exceeding 1 L/kg is lacking. Methods: Retrospective chart review at the pediatric ward of Isala, a general teaching hospital in Zwolle, The Netherlands, 100 km away from the nearest PICU. All children <18 years with impending respiratory failure treated with HFNC between January 2015 and May 2016 were included. A flowrate of 2 L/kg/minute for the first 10 kg was used; with 0.5 L/kg for every kg >10 kg and a maximum of 50 L/min. A pediatric early warning score (PEWS) comprising vital functions and work of breathing (0-28 points) was used to assess severity of respiratory distress. Treatment failure was defined as referral to the PICU. Results: In the 16-month study period HFNC was used during 41 hospital admissions in 39 patients (64.1% male), median age 6.3 months (interquartile range, IQR 3–20.6). Median (IQR) PEWS at the start of HFNC was 8.5 (7–10). Patients were diagnosed with bronchiolitis (70.7%), pneumonia (24.4%) or asthma (4.9%). In 18 cases (43.9%) HFNC failed, with referral to a PICU. No clinical variables (age, comorbidity, PEWS at admission or start of HFNC) nor improvement of the PEWS after 2 hours of HFNC were associated with treatment failure. We found no association between treatment failure and the start of HFNC at an earlier stage or at lower PEWS (odds ratio 1.03; 95% confidence interval 0.82-1.30; p=0.80). There were no safety issues, no cases with air leak or other complications. Conclusions: This small study suggests that HFNC can be safely used and initiated in a general pediatric department. We were unable to find clinical factors that predicted HFNC success. We recommend not to restrict evaluation of the effect of HFNC in studies to short-term (2 hours), but also after longer duration, at least 24 hours.

scholarly journals The Cost‑utility of Early use of High-flow Nasal Cannula in Bronchiolitis

2020 ◽  
Author(s):  
Jefferson Antonio Buendia ◽  
Ranniery Acuña-Cordero ◽  
Carlos E. Rodriguez-Martinez
Keyword(s):  
Cost Effectiveness ◽  
High Flow ◽  
Nasal Cannula ◽  
Pediatric Care ◽  
Base Case ◽  
Control Group ◽  
Emergency Setting ◽  
High Flow Nasal Cannula ◽  
Early Use ◽  
The Cost

Abstract Background: High-flow nasal cannula (HFNC) oxygen is a non-invasive ventilation system that was introduced as an alternative to CPAP (continuous positive airway pressure), with a marked increase in its use in pediatric care settings .This study aimed to evaluate the cost-effectiveness of early use of HFNC compared to oxygen by nasal cannula in an infant with bronchiolitis in the emergency setting. Methods: A decision tree model was used to estimate the cost-effectiveness of HFNC compared with oxygen by nasal cannula (control strategy) in an infant with bronchiolitis in the emergency setting. Cost data were obtained from a retrospective study on bronchiolitis from tertiary centers in Rionegro, Colombia, while utilities were collected from the literature. Results:The QALYs per patient calculated in the base-case model were 0.9141 (95% CI 0.913- 0.915) in the HFNC and 0.9105 (95% CI 0.910- 0.911) in control group. The cost per patient was US$368 (95% CI US$ 323- 411) in HFNC and US$441 (95% CI US$ 384-498) per patient in the control group.Conclusions: HFNC in emergency settings was cost-effective for the hospital treatment of an infant with bronchiolitis

High-flow nasal cannula oxygen therapy for outpatients undergoing flexible bronchoscopy: a randomised controlled trial

Thorax ◽  
2021 ◽  
pp. thoraxjnl-2021-217116
Author(s):  
Federico Longhini ◽  
Corrado Pelaia ◽  
Eugenio Garofalo ◽  
Andrea Bruni ◽  
Roberta Placida ◽  
...  
Keyword(s):  
Gas Exchange ◽  
Lung Volume ◽  
Controlled Trial ◽  
Blood Gases ◽  
High Flow ◽  
Nasal Cannula ◽  
Flexible Bronchoscopy ◽  
High Flow Nasal Cannula ◽  
Arterial Blood ◽  
Randomised Controlled

IntroductionHigh-flow nasal cannula (HFNC) provides benefits to patients undergoing flexible bronchoscopy (FOB). We compared the effects of HFNC versus standard therapy (ST) on gas exchange, lung volume and diaphragm function in patients undergoing FOB for bronchoalveolar lavage (BAL).Methods36 outpatients were randomised to ST or HFNC. Arterial blood gases, episodes of severe desaturation, changes of end-expiratory lung impedance (ΔEELI), diaphragm ultrasound were recorded. Measurements were done at baseline (T0), after bronchoscope insertion (T1), at the end of the procedure (T2) and 10 min afterwards (T3).ResultsArterial partial oxygen pressure (PaO2) was not different between T0 (10.8 (95% CI 8.7 to 12.0) kPa and T2 (11.1 (95% CI 10.4 to 12.0) kPa) with HFNC, while decreased from 11.1 (95% CI 10.5 to 12.1) to 9.1 (95% CI 8.4 to 9.8) kPa with ST. At T2, PaO2 was significantly higher with HFNC than with ST (p<0.001). Also, with HFNC, compared with ST, fewer desaturations occurred (11% vs 56%; p<0.01). ΔEELI was no different at the different time points with HFNC, while with ST there was a significant decrease at T1 (−170 (95% CI −382 to −32) mL, p=0.003), T2 (−211 (95% CI −425 to −148) mL, p<0.001) and T3 (−213 (95% CI −398 to −81) mL, p<0.001), as opposed to T0. EELI was lower with ST than HFNC at T1 (p=0.006), T2 (p=0.001) and T3 (p=0.002). Diaphragm displacement was no different between groups (p=0.748), while the thickening fraction significantly increased at T1 and T2 with ST only (p<0.01).ConclusionsDuring FOB for BAL, HFNC improves gas exchange, avoiding loss of end-expiratory lung volume and preventing increase of diaphragm activation.Trial registration numberNCT04016480.

scholarly journals Effect of post-extubation high-flow nasal cannula on reintubation in elderly patients: a retrospective propensity score-matched cohort study

2020 ◽  
Vol 14 ◽  
pp. 175346662096849
Author(s):  
Ryoung-Eun Ko ◽  
Chul Park ◽  
Jimyoung Nam ◽  
Myeong Gyun Ko ◽  
Soo Jin Na ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Propensity Score ◽  
Elderly Patients ◽  
Oxygen Therapy ◽  
High Flow ◽  
Nasal Cannula ◽  
Control Group ◽  
High Flow Nasal Cannula ◽  
Mechanically Ventilated ◽  
Clinical Benefits

Background: Studies of mechanically ventilated patients with a low risk of reintubation have suggested that the use of high-flow nasal cannula (HFNC) oxygen therapy reduces the risk of reintubation compared with conventional oxygen therapy (COT). However, the effect of HFNC following extubation in elderly patients with a high risk of reintubation remains unclear. Methods: All consecutive medical intensive care unit (ICU) patients aged >65 years who were mechanically ventilated for >24 h were prospectively registered between July 2017 and June 2018. Control was obtained from a historical database of patients attending the same ICU from January 2012 to December 2013. A total of 152 patients who underwent HFNC after planned extubation according to institutional protocols (HFNC group) were compared with a propensity-matched historical control group who underwent COT ( n = 175, COT group). The primary outcome was the proportion of reintubated patients within 48 h after planned extubation. Results: One hundred patients from the HFNC group and 129 patients from the COT group were matched by a propensity score that reflected the probability of receiving HFNC, and all variables were well matched. Post-extubation respiratory failure (41.0% versus 33.3%, p = 0.291) and reintubation rate within 48 h (16.0% versus 11.6%, p = 0.436) did not differ between the HFNC and COT groups. However, decreased levels of consciousness as a sign of post-extubation respiratory failure (27.0% versus 11.7%, p = 0.007) were significantly increased in the HFNC group compared with the COT group. Conclusion: Among elderly patients who underwent planned extubation, HFNC was not associated with a decrease in the risk of reintubation. Further prospective study evaluating the clinical benefits of post-extubation HFNC in elderly patients is needed. The reviews of this paper are available via the supplemental material section.

Sign in / Sign up

Export Citation Format

Share Document